BIOMARKERS

摘要

The present invention relates to novel biomarkers for determining the Alzheimer's disease status of a subject, and to uses of novel panels of biomarkers. AD is currently clinically diagnosed using tests of cognitive function. Studies have shown that the accuracy of the clinical diagnosis is between 65 and 90% using cognitive techniques. The present invention provides a method of determining the Alzheimer' s disease status of a subject comprising providing a sample of material obtained from the subject and determining the expression level of one or more genes selected from the group consisting of: TUBB, NEAT1, CENPB, AA482221 and CPSF3 in the sample.

主权项

1. A method of determining the Alzheimer's disease status of a subject comprising:
(a) providing a sample of material obtained from the subject; and (b) determining the expression level of one or more genes selected from the group consisting of: TUBB, NEAT1, CENPB, AA482221 and CPSF3 in the sample.